• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Neurol . Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19

tetano

Editor, Senior Moderator
J Neurol


. 2023 Jan 24.
doi: 10.1007/s00415-022-11543-8. Online ahead of print.
Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19


Roberta Ferrucci[SUP] #[/SUP][SUP] 1 2 [/SUP], Luca Cuffaro[SUP] 2 [/SUP], Antonella Capozza[SUP] 3 [/SUP], Chiara Rosci[SUP] 2 [/SUP], Natale Maiorana[SUP] 1 [/SUP], Elisabetta Groppo[SUP] 2 [/SUP], Maria Rita Reitano[SUP] 2 [/SUP], Barbara Poletti[SUP] 4 [/SUP], Nicola Ticozzi[SUP] 4 5 [/SUP], Luca Tagliabue[SUP] #[/SUP][SUP] 3 [/SUP], Vincenzo Silani[SUP] 4 5 [/SUP], Alberto Priori[SUP] 6 7 [/SUP]



Affiliations

Abstract

Emerging evidence indicates that the etiologic agent responsible for coronavirus disease 2019 (COVID-19), can cause neurological complications. COVID-19 may induce cognitive impairment through multiple mechanisms. The aim of the present study was to describe the possible neuropsychological and metabolic neuroimaging consequences of COVID-19 12 months after patients' hospital discharge. We retrospectively recruited 7 patients (age [mean ± SD] = 56 years ± 12.39, 4 men) who had been hospitalized for COVID-19 with persistent neuropsychological deficits 12 months after hospital discharge. All patients underwent cognitive assessment and brain ([SUP]18[/SUP]F-FDG) PET/CT, and one also underwent [SUP]18[/SUP]F-amyloid PET/CT. Of the seven patients studied, four had normal glucose metabolism in the brain. Three patients showed various brain hypometabolism patterns: (1) unilateral left temporal mesial area hypometabolism; (2) pontine involvement; and (3) bilateral prefrontal area abnormalities with asymmetric parietal impairment. The patient who showed the most widespread glucose hypometabolism in the brain underwent an [SUP]18[/SUP]F-amyloid PET/CT to assess the presence of Aβ plaques. This examination showed significant Aβ deposition in the superior and middle frontal cortex, and in the posterior cingulate cortex extending mildly in the rostral and caudal anterior cingulate areas. Although some other reports have already suggested that brain hypometabolism may be associated with cognitive impairment at shorter intervals from SarsCov-2 infection, our study is the first to assess cognitive functions, brain metabolic activity and in a patient also amyloid PET one year after COVID-19, demonstrating that cerebral effects of COVID-19 can largely outlast the acute phase of the disease and even be followed by amyloid deposition.

Keywords: 18F-amyloid PET/CT; COVID-19; Cognitive function; Hypometabolism; Long COVID.
 
Back
Top Bottom